About this trial
Traditional and transcatheter surgical treatments of severe aortic valve stenosis (SAVS) are increasing in parallel with the improved life-expectancy. Recent randomized trials (RCTs) reported comparable or non-inferior mortality with transcatheter treatments compared to traditional surgery. However, RCTs have the limitation of being a mirror of the predefined inclusion/exclusion criteria, without reflecting the "real clinical world".
Technological improvements have recently allowed the development of minimally invasive surgical accesses and the use of sutureless valves, but their impact on the clinical scenario is difficult to assess because of the monocentric design of published studies and limited sample-size. A prospective multicentre registry including all patients referred for a surgical treatment of SAVS (traditional, through full-sternotomy; minimally-invasive; or transcatheter; with both "sutured" and "sutureless" valves) will provide a "real-world" picture of available results of current surgical options, and will help to clarify the "grey zones" of current guidelines.
E-AVR is a prospective observational open registry designed to collect all data from patients admitted for SAVS, with or without coronary artery disease, in 16 cardiac surgery Centres located in six countries (France, Germany, Italy, Spain, Switzerland, and United Kingdom). Patients will be enrolled over a 2-year period and followed-up for a minimum of 5 years to a maximum of 10 years after enrolment. Outcome definitions are concordant with VARC-2 criteria and established guidelines. Primary outcome is 5-year all-cause mortality. Secondary outcomes aim at establishing "early" 30-day all-cause and cardiovascular mortality, as well as major morbidity, and "late" cardio-vascular mortality, major morbidity, structural and non-structural valve complications, quality of life and echocardiographic results.
The study protocol is approved by Local Ethics Committees. Any formal presentation or publication of data will be considered as a joint publication by the participating physician(s) and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE) for authorship.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age >18 yy
Isolated SAVS with or without concomitant aortic valve regurgitation
Isolated prosthetic aortic dysfunction
SAVS + coronary artery disease (CAD)
Disqualifiers
Patients undergoing concomitant mitral valve surgery, or tricuspid valve surgery, or aortic surgery (i.e. composite aortic valve and ascending aorta replacement with or without circulatory arrest), or atrial fibrillation surgery, or any other associated cardiac surgical procedure (with the exception of CABG)
Concomitant aortic root procedure (i.e. Bentall operation, David operation, homografts, autografts)
SAVR with techniques of aortic annular enlargement
Porcelain aorta
Trial population
All patients referred for a surgical treatment of severe aortic valve stenosis (either traditional - through full-sternotomy - or minimally-invasive, or transcatheter - with both "sutured" and "sutureless" valves), isolated or associated with coronary artery bypass grafting
Trial design
Cohort
Prospective
Treatments tested in this trial
Aortic valve replacement
Procedure/SurgeryAll surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
Treatment groups
Trial outcomes
Primary outcomes
5-year all-cause mortality
Any death occurring after surgery
Secondary outcomes
Follow-up all-cause mortality
Any death occurring after surgery
Cardiovascular mortality
Every death caused by cardiovascular events
Stroke
Any ischemic brain injury occurring after surgery and lasting \> 24 hours
Acute myocardial infarction
Myocardial infarction (diagnosed by ECG and troponin monitoring) any time after surgery
Other outcomes
Quality of Life
It will be based on eight questionnaire items reported in Short-Form 8 Health Survey questionnaire
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Parma
Lead sponsor
Universita di Verona
Sponsor institution
University of Genova
Collaborator
University Hospitals, Leicester
Collaborator
University of Hamburg-Eppendorf
Collaborator
San Camillo Hospital, Rome
Collaborator
University of Turin, Italy
Collaborator
Centre Hospitalier Universitaire de Besancon
Collaborator
University Hospital, Udine, Italy
Collaborator
Hospital Clinic of Barcelona
Collaborator
University of Lausanne Hospitals
Collaborator
Hopital Universitaire Robert-Debre
Collaborator
Paracelsus Medical University
Collaborator
University of Campania Luigi Vanvitelli
Collaborator
University of Texas, Southwestern Medical Center at Dallas
Collaborator
Clinique Pasteur
Collaborator
Cardiocentro Ticino
Collaborator
Universita di Verona
Collaborator